Coinbase hit with wave of lawsuits over customer data breaches
Coinbase has been hit with a flood of lawsuits after it recently disclosed its user data was breached, with users accusing the crypto exchange of mishandling the incident.
At least six lawsuits were filed against Coinbase between May 15 and May 16, which all made various claims that the exchange failed to keep stringent security protocols to protect user data and handled the data breach aftermath poorly.
In one of the lawsuits, filed in a New York federal court on May 16, plaintiff Paul Bender argued that Coinbase failed to protect the sensitive personal information of millions of users during the data breach.
Users are suing Coinbase, alleging the exchange failed to protect their sensitive data. Source: PACER
Coinbase reported on May 15 that four days earlier it had been hit with a $20 million extortion attempt after cybercriminals bribed several of its customer support agents to access internal systems and steal a limited amount of user account data.
The stolen data included names, addresses, phone numbers, emails, the last four digits of Social Security numbers, some bank account identifiers, driver's licenses, passports and some account data, such as balance snapshots and transaction history.
Bender claimed that 'Coinbase failed to implement and maintain reasonable security safeguards,' which exposed users to 'serious and ongoing risks.'
The suit also claimed Coinbase's response to the incident was 'inadequate, fragmented, and delayed.'
'Users were not promptly or fully informed of the compromise, and Coinbase did not immediately take meaningful steps to mitigate further harm, provide identity protection services, or offer actionable guidance to affected individuals,' the complaint claimed.
The lawsuit claimed users could face 'substantial, immediate, and ongoing threat of identity theft and financial fraud' and that the consequences of the breach could be long-term or 'potentially permanent' because the compromised information can't be recovered or made secure once exposed. Flurry of lawsuits make similar allegations
Two other lawsuits filed in a New York federal court made similar claims against Coinbase, while a fourth lawsuit added the allegation of unjust enrichment, arguing that Coinbase didn't spend enough on data security measures.
All four complaints ask for damages and other measures to help protect the plaintiff's sensitive data.
Meanwhile, a fifth lawsuit filed in a California federal court on May 15 made similar claims against Coinbase, but asked the court to order Coinbase to purge all sensitive data it holds about the plaintiffs and hire third-party security auditors to test its security systems, among other requests.
A Coinbase spokesperson did not comment on the lawsuits and instead pointed Cointelegraph to a blog post it shared regarding the data breaches.
Coinbase said it refused to pay the $20 million ransom and has flagged plans to reimburse users tricked into sending crypto to phishing scammers due to the data breach.
In a filing with the US Securities and Exchange Commission, the exchange said it expects reimbursement expenses ranging from $180 million to $400 million.
The exchange also reportedly fired a group of customer support agents based in India following their alleged involvement in social engineering attacks on users.
Coinbase (COIN) shares dipped 7% and dropped to $244 after it disclosed the data breach along with an ongoing SEC probe over misstated user numbers in 2021.
The stock has since staged a comeback, spiking 9% and hitting $266 by the closing bell on May 16, according to Google Finance.
Source: https://cointelegraph.com/news/coinbase-wave-of-lawsuits-over-customer-data-breaches
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13-06-2025
- Globe and Mail
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CNA
13-06-2025
- CNA
Sean 'Diddy' Combs' lawyer complains about trial secrecy as a famous rapper's name goes unmentioned
A lawyer for Sean 'Diddy' Combs protested the rising tide of secrecy at the hip-hop icon's federal sex trafficking and racketeering trial on Thursday (Jun 12) after Combs and the public were excluded from arguments over whether another famous rapper's name could be disclosed. Defence attorney Marc Agnifilo complained to Judge Arun Subramanian after Combs was excluded from a meeting outside the courtroom between lawyers and the judge. That meeting delayed the final day of weeklong testimony from a woman identified in court only by the pseudonym 'Jane', who dated Combs from 2001 until his September arrest. When her emotional testimony ended, she hugged a prosecutor, Maureen Comey, in front of the jury, which would have drawn an outcry from the defence except she hugged defence attorney Teny Geragos too. Her testimony likely helped both sides. She admitted still loving Combs, but she said she now resents that she felt forced to have sex with strangers to satisfy his sexual fantasies. Combs, 55, has pleaded not guilty to charges that carry a potential prison sentence of 15 years to life in prison. Prosecutors say he used fame, fortune, violence and threats to manipulate girlfriends into sex with paid sex workers in multi-day events that they later regretted. Defence attorneys say the government is prosecuting consensual sex between adults. Under cross-examination by Geragos, Jane testified Thursday that she flew to Las Vegas in January 2023 with a famous rapper and his girlfriend. Geragos didn't identify the rapper but asked Jane if he had recorded with Combs, 'an individual at the top of the music industry as well ... an icon in the music industry'. She also asked if Combs and the rapper were 'really close'. 'Yes,' Jane replied. Once in Las Vegas, Jane testified, she went with a group including the rapper to dinner, a strip club and a hotel room party, where a sex worker had sex with a woman while a half-dozen others watched. She said there was dancing and the rapper said, 'hey beautiful', and told her he'd always wanted to have sex with her. Jane said she didn't recall exactly when but she flashed her breasts while dancing. The testimony followed the closed-door session Thursday, when lawyers discussed what facts could be disclosed about the hotel room encounter. Agnifilo said the need for a public trial was 'an important issue, a constitutional issue' and objected to so much happening out of the earshot of his client. In response, the judge offered more secrecy, saying 'If your client wishes to be heard ... we can clear this courtroom if need be to address it.' Agnifilo rejected the offer. 'Part of the reason trials are fully public is so if other people realise they know something about an event discussed in a public courtroom, they can come forward and share their recollection of it,' the lawyer said, adding: 'That is kind of the practical side of the constitutional right to a public trial.' A monitor that is used to show exhibits to spectators has been shut off throughout Jane's testimony, although lawyers, the judge, Combs and jurors can view them. Some sidebar conversations between lawyers and the judge have been sealed. The judge also has banned the public from viewing any exhibits containing sexual content, even though the defence has said images from the group sex episodes proves they were consensual acts between adults, and not proof of crimes. And many of the letters to the judge from lawyers each day are filed under seal, preventing the public from quickly knowing, for instance, the details about why prosecutors want a black juror ejected from the jury in mid-trial. The judge has said he'll decide the juror's fate Friday. Defence attorney Alexandra Shapiro has called the prosecution's quest a 'thinly veiled effort to dismiss a black juror'. Jane and Casandra 'Cassie' Ventura, who testified for four days in the trial's first week about her relationship with Combs from 2007 through 2018, both said they participated in the sex marathons for years, with Cassie calling them 'freak-off' nights and Jane referring to them as 'hotel nights'. Agnifilo said the defence consented to Jane testifying with a pseudonym but did not consent to other events related to her testimony and the testimony of other witnesses not being public.
Globe and Mail
13-06-2025
- Globe and Mail
Tyler Technologies: A Strong Contender in Government Software Solutions
Explore the exciting world of Tyler Technologies (NYSE: TYL) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 7, 2025. The video was published on Jun. 12, 2025. Should you invest $1,000 in Tyler Technologies right now? Before you buy stock in Tyler Technologies, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tyler Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
